| 4.29 0.15 (3.62%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.26 | 1-year : | 6.15 |
| Resists | First : | 4.51 | Second : | 5.26 |
| Pivot price | 4.12  |
|||
| Supports | First : | 3.9 | Second : | 3.52 |
| MAs | MA(5) : | 4.21 |
MA(20) : | 4.12 |
| MA(100) : | 3.81 |
MA(250) : | 3.38 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 66.1 |
| RSI | RSI(14): 55.4 |
|||
| 52-week | High : | 6.63 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XFOR ] has closed below upper band by 22.1%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.38 - 4.4 | 4.4 - 4.42 |
| Low: | 4.14 - 4.16 | 4.16 - 4.18 |
| Close: | 4.25 - 4.29 | 4.29 - 4.32 |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Thu, 02 Apr 2026
XFOR SEC Filings - X4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Thu, 02 Apr 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Wed, 01 Apr 2026
New X4 hires get stock options priced at $4.13 a share - Stock Titan
Sun, 22 Mar 2026
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Tue, 17 Mar 2026
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Tue, 17 Mar 2026
X4 Pharmaceuticals Reports Positive EMA Opinion on Mavorixafor and Updates on 4WARD Phase 3 Trial Enrollment Progress - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 90.2 (%) |
| Shares Short | 3,500 (K) |
| Shares Short P.Month | 3,380 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.04 |
| Profit Margin | -225.6 % |
| Operating Margin | -930.7 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -76 % |
| Qtrly Rev. Growth | 79 % |
| Gross Profit (p.s.) | 0.32 |
| Sales Per Share | 0.38 |
| EBITDA (p.s.) | -0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -86 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -2.3 |
| PEG Ratio | 0 |
| Price to Book value | 2.09 |
| Price to Sales | 11.1 |
| Price to Cash Flow | -4.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|